What it reads. Cancer cells die faster than healthy ones and leak DNA fragments into the bloodstream. The test reads the chemical tags on those fragments, spots a shared cancer signal across fifty-plus tumour types, and names the one or two body sites most likely to be the source 1. It works best when there's plenty of cancer to find: sensitivity runs about 17% at stage I and 90% at stage IV 1.
The case for it. Two thirds of US cancer deaths come from cancers with no recommended screen 2. This is the first tool aimed at that gap. In the biggest healthy-adult trial, roughly three early-stage cancers were caught per thousand people screened, and a positive result was truly cancer about 62% of the time 3.
The case against it. The world's first randomised trial, in 142,250 UK adults, missed its main goal in June 2026. Late-stage diagnoses across all cancers didn't fall meaningfully. In the twelve deadliest, stage IV diagnoses dropped 22–26% and early catches rose 16%, but whether that saves lives won't be known until around 2030 4.
This is an add-on, not a replacement. The question is never this instead of your colonoscopy — it's whether to layer it on top, at your own cost, for a shot at a cancer nothing else screens for.
What a good outcome looks like. For the rare person whose test catches an early version of a deadly cancer, the swing is large: pancreatic cancer at stage I runs about 40% five-year survival versus 3% at stage IV; ovarian, roughly 90% versus 30%. For the other 996 in 1,000 screened in a year, the result is reassurance, a false-alarm scare, or nothing. A negative doesn't change a thing you were already going to do.
The fine print — when to skip it, and what people get wrong
"Screens fifty cancers" means detects, not catches — prostate and kidney sensitivity is under 20%, brain doesn't register 1. A negative isn't a clean bill: it misses 60–70% of cancers per round 4.
False positives dominate the harm: 92% of positives get imaging, 30% of false alarms an invasive procedure, and five months of dread 3. The signal points to the wrong organ in 8–15% of true positives 5.
- 1Klein EA, Richards D, Cohn A, et al. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of Oncology. link
- 2USPSTF (2024). U.S. Preventive Services Task Force A and B Recommendations on Cancer Screening. link
- 3Schrag D, Beer TM, McDonnell CH 3rd, et al. (2023). Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. The Lancet. link
- 4Sasieni P, Smittenaar R, Hubbell E, et al. (2026). Three-year results from the NHS-Galleri randomised controlled trial of multi-cancer early detection screening (NCT05611632). ASCO Annual Meeting. link
- 5Pangaluri S, Niman SM, Forman HP, et al. (2025). Multi-Cancer Early Detection Tests: State of the Art and Implications for Radiologists. Radiology. link
დაკავშირებული სახელმძღვანელოში (5)
- — Before paying for a multi-cancer blood test, make sure the proven screens on this schedule are actually done — they save lives the blood test hasn't yet shown it does.
- — Colonoscopy or stool testing is a proven screen with real mortality benefit — don't let a multi-cancer blood test crowd it out.
- — If you qualify for lung CT screening, that's the evidence-backed test; a multi-cancer blood panel hasn't yet earned the same standing.
- — Whether a $949 blood test is worth it comes down to the numbers — how many people it actually helps versus alarms; this is how to read that.
- — A blood-based multi-cancer test is the new alternative being pitched against single-cancer screens like PSA.
Multi-Cancer Early Detection Tests
One venous blood draw, no fasting, results in 10 working days (SchragEtAl2023). The test itself is trivial; the downstream effort if positive (imaging cascade, biopsy, weeks-to-months of diagnostic resolution) is substantial but conditional on a positive result and not part of the base action.
List price $949 per test; reduced self-pay around $799; annual screening as marketed places this in the $500-2,000/year ongoing band. Not covered by Medicare or most private insurers pending FDA decision; TRICARE covers only once-per-lifetime since mid-2025. Downstream false-positive workup (PET-CT, biopsy) adds variable additional cost when triggered.
Three large prospective observational datasets (CCGA-3, PATHFINDER, SYMPLIFY) establish technical performance; one randomised controlled trial (NHS-Galleri, N=142,250, three annual rounds) read out at ASCO 2026 and missed its pre-specified primary endpoint of significant late-stage reduction (NHSGalleri2026). Mechanism is sound (Klein2021) but stage-I sensitivity is 10-25%, mortality data are pending, and no regulatory body has approved MCED for population screening. Sparse / contested literature with plausible mechanism — score 2.
Plausible but unconfirmed mortality benefit. NHS-Galleri (N=142,250) reduced stage IV diagnoses by 14% overall and 22-26% in twelve targeted cancers across three annual rounds, but missed its pre-specified primary endpoint for late-stage reduction; mortality data are years from maturity (NHSGalleri2026). PATHFINDER 2 detected stage I-II cancer in roughly 3 per 1,000 screened (SchragEtAl2023). Until mortality readout, longevity score reflects marginal contested contribution rather than established effect.